The company uses its proven protected diamagnetic microarray technology in both skin care and joint inflammation products.
Showing 25 of 293
The company will hold a general meeting on July 19 seeking approval for the appointment of Embark Ventures.
1,000 patients have now been prescribed Althea medicinal cannabis products in Australia.
Canopy Growth Corporation has exercised options valued at more than $1.535 million and now holds in excess of 42 million shares.
Wagner played a key role in the medicinal cannabis company’s acquisition of land in Toowoomba for construction of greenhouses
The company is targeting the treatment of chronic pain in Australia while exploring global export opportunities and expansion into additional medical areas.
An Australian fund manager has increased its stake to 19.61% in the company.
MMJ is a global cannabis investment company with a portfolio of listed and unlisted holdings.
A number of board members have purchased shares in the company in 2019 to date.
The Australian-based bio-pharmaceutical company has also formed a strategic relationship with European medicinal cannabis group HAPA Medical BV to access HAPA’s EU-GMP grade manufacturing capabilities.
The company was recently awarded a patent for a novel prognostic biomarker for breast cancer.
This purchase follows recent buying from the company’s board’s chairman.
The dealer licence which was previously under the narcotic control regulations of the controlled drugs and substances act, has now been changed to the recently enacted cannabis act and cannabis regulations.
In the near term the company will continue its focus on the production of medicinal cannabis at its existing southern and northern facilities in Melbourne for supply to Australian patients.
The installation represents the company’s third agricultural sale to Dagan and follows substantial orders $323,000 and $278,000 respectively.
This follows chairman Geoff Starr’s on-market share purchases last month.
The GFS solution provides storage and distribution capabilities to automate and streamline the Polaris facility’s nutrient lifecycle planning.
Australian-based YPB Group said Namaste will apply its authenticity product markers to all products on Namaste's e-commerce platforms
80,000 shares at a cost of $10,193 represents a 12.7 cents per share average cost price.
The company expects to supply medicinal cannabis to patients from around March 2019.
The company has finalised negotiations with California-based company VaporSpec.
The company has purchased the property for $2.6 million in the Northern Rivers district of NSW.
Quentin Megson will serve jointly in the role with existing company secretary Susan Hunter.
The Root Zone Temperature Optimisation (RZTO) technology stabilises plant root zone temperatures, optimising plant physiology.
Non-executive director Max Johnston now holds 200,000 shares in an indirect interest.